Claudio Vinegoni, Ph.D. | Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging

Theranostics
Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging

Mikula, H., Stapleton, S., Kohler, R. H., Vinegoni, C., and Weissleder^#, R.

Theranostics 2017

ABS URL PMID DOI PMCID CITE HTML PDF

Herein we describe fluorescent derivatives of vemurafenib to probe therapeutic BRAF inhibition in live cells and in vivo. The compounds were evaluated and compared by determining target binding, inhibition of mutant BRAF melanoma cell lines and live cell imaging. We show that vemurafenib-BODIPY is a superior imaging drug to visualize the targets of vemurafenib in live cells and in vivo in non-resistant and resistant melanoma tumors.
@article{2017-THERA, author= {Mikula, H. and Stapleton, S. and Kohler, R. H. and Vinegoni, C. and Weissleder<sup>#</sup>, R.}, title= {Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging}, journal= {Theranostics}, alternatejournal = {Theranostics}, year = {2017}, volume = {7}, number = {5}, pages = {1257-1265}, issn = {1838-7640}, doi = {10.7150/thno.18238}, pmcid = {PMC5399591}, pmid= {28435463} }
28435463

PMC5399591

10.7150/thno.18238

Abstract

"Herein we describe fluorescent derivatives of vemurafenib to probe therapeutic BRAF inhibition in live cells and in vivo. The compounds were evaluated and compared by determining target binding, inhibition of mutant BRAF melanoma cell lines and live cell imaging. We show that vemurafenib-BODIPY is a superior imaging drug to visualize the targets of vemurafenib in live cells and in vivo in non-resistant and resistant melanoma tumors."

Full citation

For attribution in academic contexts, please cite this work as:

Mikula, H., Stapleton, S., Kohler, R. H., Vinegoni, C., & Weissleder^#, R. (2017). Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging. Theranostics, 7(5), 1257–1265. https://doi.org/10.7150/thno.18238